Alexion Pharma (ALXN) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Alexion Reports First Quarter 2016 Results
April 28, 2016 6:30 AM EDTTotal Revenues of $701 Million; Increased 17 Percent Year-on-Year; 22 Percent Increase Year-on-Year on a Constant Currency Basis
Soliris® (eculizumab) Revenues Driven by Steady Number of New Patients Treated in the U.S., Europe and Japan
Strensiq® (asfotase alfa) Launch Off to a Strong Start in Initial Countries
Kanuma® (sebelipase alfa) U.S. Launch Under Way
Exceeded Target Enrollment for Two Initial Studies of ALXN1210 in Patients with PNH
Commenced Dose Escalation for SBC-103 in Phase 1/2 Study in Patients with MPS IIIB
Progressed Three Registration Studies... More
